Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > EMA issue

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 21, 2021 3:32pm

105 Views

Post# 33038713

RE:RE:RE:EMA issue

The first question (FDA) wasn't easy to hear the second one (EMA) sounds clear on my end maybe Paul mixed it up but I doubt it. If you want to check it's about 29 minutes in to conference.

SPCEO1 wrote: I feel pretty sure that the audio issues from the questioner meant that Paul did not hear that the question was about the EMA and therefore answered it as if it was the FDA.

scarlet1967 wrote: The question which was asked was specifically about EMA, his answer was,
"the meeting is just round the corner it's coming up for NASH we are going to do it in a few week in a few months we will actually resubmit the protocol we are on schedule to dose first patient in Q3".

SPCEO1 wrote: Someone said Paul addressed the EMA issue in today's Bloom Burton call. I didn't hear that but may have missed it. In the Q&A, a EMA question was asked but due to the bad audio, I think Paul thought the question was about the FDA and answered it (actually re-answered it might be a better description since he had already addressed the FDA meeting) as if the question was again about the FDA meeting. So, I did not hear any new insight regarding the FDA on the call. Did I miss something?